secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001654954-24-007415
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences prices $8M public offering of common stock and warrants
---------------------------------------------------------------------------

- Gross proceeds ~$8M; offering closed June 5, 2024 with Craig-Hallum as placement agent.
- 61.5M units sold at $0.13 each (or pre-funded at $0.1299), each with Series A and B warrants.
- Series A and B warrants exercisable at $0.22; Series B includes alternate cashless exercise at $0.001 for 3 shares.
- Warrants require stockholder approval and charter amendment; lock-up of 90 days for company/insiders.
- Net proceeds to be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424007415/0001654954-24-007415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424007415/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-007415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer